Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Andreas Busch

Working with our healthcare system more closely is vital

Bayer’s Lars Bruening on partnership working amid environmental challenges

- PMLiVE

Shire says all its studies will publish in open access journals

The Irish biotech says its focus on rare diseases was a key factor behind the decision

Shire wins FDA approval for haemophilia dosing software

The web-based myPKFiT supports the pharma firm's Advate treatment

- PMLiVE

Shire claims EU approval for haemophilia A drug Adynovi

The drug will battle Bayer’s Kovaltry and Sobi's Elocta in a bid to capture market share

- PMLiVE

Shire separates out neuroscience as it considers its future

Follows last year's strategic review at the Irish biotechnology firm

Shire Basingstoke

Shire’s Maribavir wins US breakthrough therapy designation

It's based on phase II data for the transplant infection treatment

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

- PMLiVE

Shire suffers pipeline failure as takeover speculation builds

Several big pharma companies are reportedly considering bids

Andy Busch joins Shire as its CSO and head of research and development

And Howard Mayer is promoted to chief medical officer

Bayer symbol

Bayer gets clinical data to support $1.5bn Loxo deal

Larotrectinib’s response rate likely to be practice changing

Bayer symbol

Joerg Moeller to head Bayer R&D after operational shake-up

Andreas Busch to move to Shire as head of R&D and CSO

- PMLiVE

Regeneron and Bayer drop AMD combination

Abandon plans after disappointing phase II trial results

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links